{"id":20177,"date":"2024-08-16T11:24:39","date_gmt":"2024-08-16T15:24:39","guid":{"rendered":"https:\/\/www.ices.on.ca\/?post_type=public_project&#038;p=20177"},"modified":"2026-03-11T13:49:15","modified_gmt":"2026-03-11T17:49:15","slug":"the-impact-of-different-classes-of-anti-rheumatic-medications-on-acute-health-care-utilization-and-all-cause-mortality-in-elderly-rheumatoid-arthritis-patients","status":"publish","type":"public_project","link":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/the-impact-of-different-classes-of-anti-rheumatic-medications-on-acute-health-care-utilization-and-all-cause-mortality-in-elderly-rheumatoid-arthritis-patients\/","title":{"rendered":"The impact of different classes of anti-rheumatic medications on acute health care utilization and all-cause mortality in elderly rheumatoid arthritis patients"},"content":{"rendered":"<p><strong>Project ID:<\/strong> 2023-1098\/ TRIM 2025 0970 385 000<\/p>\n<p><strong>Principal Investigator:<\/strong> Mohammad Movahedi<\/p>\n<p><strong>Description:<\/strong> The Oral Rheumatoid Arthritis Trial (ORAL) Surveillance study reported an increased risk of major adverse cardiovascular events (MACE) and cancer in patients with RA taking tofacitinib compared to Tumor Necrosing Factor Inhibitors (TNFi). However, there is limited real world evidence. Using data from Ontario Rheumatoid Arthritis Database (ORAD) and Ontario drug Benefit database (ODBD) held at ICES, the project team will investigate the risk of all-cause emergency department visits and hospitalization and mortality across different classes of anti-rheumatic medication in the RA population over 65 years old. The project will specifically look at hospitalization due to MACE and cancer in Janus Kinase inhibitor (JAKi) users compared to TNFi users. The findings will assist rheumatologists across Ontario choose an advanced therapy that will minimize serious side effects.<\/p>\n<p><strong>PIA approved:<\/strong> April 2, 2024<\/p>\n<p><strong>Status:<\/strong> In progress<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Project ID: 2023-1098\/ TRIM 2025 0970 385 000 Principal Investigator: Mohammad Movahedi Description: The Oral Rheumatoid Arthritis Trial (ORAL) Surveillance study reported an increased risk of major adverse cardiovascular events (MACE) and cancer in patients with RA taking tofacitinib compared to Tumor Necrosing Factor Inhibitors (TNFi). However, there is limited real world evidence. Using data [&hellip;]<\/p>\n","protected":false},"template":"","organization_type":[],"project_status":[104],"response_type":[],"class_list":["post-20177","public_project","type-public_project","status-publish","hentry","project_status-in-progress"],"acf":{"project_id":"2023-1098\/ TRIM 2025 0970 385 000","project_id_year":2024,"ices_scientist":"","principal_investigators":null,"knowledge_user":"","client":"","objectives":"","results":"","availability_of_results":"","pia_approved":null,"infographic":"","sitecore_item_id":"","sitecore_item_name":"","sitecore_field_values":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The impact of different classes of anti-rheumatic medications on acute health care utilization and all-cause mortality in elderly rheumatoid arthritis patients | ICES<\/title>\n<meta name=\"description\" content=\"Project ID: 2023-1098\/ TRIM 2025 0970 385 000 Principal Investigator: Mohammad Movahedi Description: The Oral Rheumatoid Arthritis Trial (ORAL)\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/the-impact-of-different-classes-of-anti-rheumatic-medications-on-acute-health-care-utilization-and-all-cause-mortality-in-elderly-rheumatoid-arthritis-patients\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The impact of different classes of anti-rheumatic medications on acute health care utilization and all-cause mortality in elderly rheumatoid arthritis patients | ICES\" \/>\n<meta property=\"og:description\" content=\"Project ID: 2023-1098\/ TRIM 2025 0970 385 000 Principal Investigator: Mohammad Movahedi Description: The Oral Rheumatoid Arthritis Trial (ORAL)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/the-impact-of-different-classes-of-anti-rheumatic-medications-on-acute-health-care-utilization-and-all-cause-mortality-in-elderly-rheumatoid-arthritis-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-11T17:49:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/public-sector-projects\\\/the-impact-of-different-classes-of-anti-rheumatic-medications-on-acute-health-care-utilization-and-all-cause-mortality-in-elderly-rheumatoid-arthritis-patients\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/public-sector-projects\\\/the-impact-of-different-classes-of-anti-rheumatic-medications-on-acute-health-care-utilization-and-all-cause-mortality-in-elderly-rheumatoid-arthritis-patients\\\/\",\"name\":\"The impact of different classes of anti-rheumatic medications on acute health care utilization and all-cause mortality in elderly rheumatoid arthritis patients | ICES\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2024-08-16T15:24:39+00:00\",\"dateModified\":\"2026-03-11T17:49:15+00:00\",\"description\":\"Project ID: 2023-1098\\\/ TRIM 2025 0970 385 000 Principal Investigator: Mohammad Movahedi Description: The Oral Rheumatoid Arthritis Trial (ORAL)\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/public-sector-projects\\\/the-impact-of-different-classes-of-anti-rheumatic-medications-on-acute-health-care-utilization-and-all-cause-mortality-in-elderly-rheumatoid-arthritis-patients\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/public-sector-projects\\\/the-impact-of-different-classes-of-anti-rheumatic-medications-on-acute-health-care-utilization-and-all-cause-mortality-in-elderly-rheumatoid-arthritis-patients\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/public-sector-projects\\\/the-impact-of-different-classes-of-anti-rheumatic-medications-on-acute-health-care-utilization-and-all-cause-mortality-in-elderly-rheumatoid-arthritis-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Public Sector Projects\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/public-sector-projects\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"The impact of different classes of anti-rheumatic medications on acute health care utilization and all-cause mortality in elderly rheumatoid arthritis patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The impact of different classes of anti-rheumatic medications on acute health care utilization and all-cause mortality in elderly rheumatoid arthritis patients | ICES","description":"Project ID: 2023-1098\/ TRIM 2025 0970 385 000 Principal Investigator: Mohammad Movahedi Description: The Oral Rheumatoid Arthritis Trial (ORAL)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/the-impact-of-different-classes-of-anti-rheumatic-medications-on-acute-health-care-utilization-and-all-cause-mortality-in-elderly-rheumatoid-arthritis-patients\/","og_locale":"fr_FR","og_type":"article","og_title":"The impact of different classes of anti-rheumatic medications on acute health care utilization and all-cause mortality in elderly rheumatoid arthritis patients | ICES","og_description":"Project ID: 2023-1098\/ TRIM 2025 0970 385 000 Principal Investigator: Mohammad Movahedi Description: The Oral Rheumatoid Arthritis Trial (ORAL)","og_url":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/the-impact-of-different-classes-of-anti-rheumatic-medications-on-acute-health-care-utilization-and-all-cause-mortality-in-elderly-rheumatoid-arthritis-patients\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2026-03-11T17:49:15+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/the-impact-of-different-classes-of-anti-rheumatic-medications-on-acute-health-care-utilization-and-all-cause-mortality-in-elderly-rheumatoid-arthritis-patients\/","url":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/the-impact-of-different-classes-of-anti-rheumatic-medications-on-acute-health-care-utilization-and-all-cause-mortality-in-elderly-rheumatoid-arthritis-patients\/","name":"The impact of different classes of anti-rheumatic medications on acute health care utilization and all-cause mortality in elderly rheumatoid arthritis patients | ICES","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2024-08-16T15:24:39+00:00","dateModified":"2026-03-11T17:49:15+00:00","description":"Project ID: 2023-1098\/ TRIM 2025 0970 385 000 Principal Investigator: Mohammad Movahedi Description: The Oral Rheumatoid Arthritis Trial (ORAL)","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/the-impact-of-different-classes-of-anti-rheumatic-medications-on-acute-health-care-utilization-and-all-cause-mortality-in-elderly-rheumatoid-arthritis-patients\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/the-impact-of-different-classes-of-anti-rheumatic-medications-on-acute-health-care-utilization-and-all-cause-mortality-in-elderly-rheumatoid-arthritis-patients\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/the-impact-of-different-classes-of-anti-rheumatic-medications-on-acute-health-care-utilization-and-all-cause-mortality-in-elderly-rheumatoid-arthritis-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Public Sector Projects","item":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/public-sector-projects\/"},{"@type":"ListItem","position":3,"name":"The impact of different classes of anti-rheumatic medications on acute health care utilization and all-cause mortality in elderly rheumatoid arthritis patients"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/public_project\/20177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/public_project"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/public_project"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=20177"}],"wp:term":[{"taxonomy":"organization_type","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/organization_type?post=20177"},{"taxonomy":"project_status","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/project_status?post=20177"},{"taxonomy":"response_type","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/response_type?post=20177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}